High-throughput screening platform of delivery vehicles for in vivo delivery
Patent Information
- Application Number
- PCT/CN2024/091283
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-06
- Publication Date
- 2024-11-21
Smart Images

Figure PCTCN2024091283-FTAPPB-I100001 
Figure PCTCN2024091283-FTAPPB-I100002 
Figure PCTCN2024091283-FTAPPB-I100003
Abstract
Description
High-throughput screening platform of delivery vehicles for in vivo deliveryTechnical Field
[0001] This application claims the priority to PCT application No. PCT / CN2023 / 093940 filed on May 12, 2023. The entire contents of the aforementioned applications are hereby incorporated by reference.Background
[0002] Nanoparticle libraries, consisting of hundreds to thousands of LNPs, can be screened in vitro. This process is only efficient ifit predicts in vivo (in a living animal) delivery. In vivo mRNA delivery is affected by pulsatile blood flow, heterogenous vasculature, and clearance by the kidney, spleen, liver, lymphatics, and immune system. Barcoding technologies have quantified LNP biodistribution, which is necessary, but not sufficient, for cytoplasmic nucleic acid delivery. And the genes that alter whether the nanoparticle escapes into the endosome are likely to vary with each cell type. As a result, it is not possible to predict functional delivery of drug into the cytoplasm or nucleus by measuring biodistribution. Current technologies like gene editing require cargo to function at the genomic level, yet existing screening methods struggle to accurately reflect the optimal delivery strategy for the ultimate goal. Moreover, current methods impose significant restrictions on the types of delivery vehicles that can be screened, with many being incompatible with these methods.
[0003] A method is needed to characterize and screen delivery vehicles that exhibit the desired tropism and deliver functional cargo to specific cells or tissues, and this method should be applicable to a wide variety of delivery systems.
[0004] Content of the present invention
[0005] This disclosure provides a method for characterizing delivery vehicles for in vivo delivery of an agent comprising:
[0006] (a) formulating multiple delivery vehicles having different chemical compositions, wherein each different delivery vehicle comprises: a) one or more biologically active agents, and b) one or more identifiers that identify the composition of the delivery vehicle;
[0007] (b) administering the multiple delivery vehicles to the cells or to the subject; and
[0008] (c) identifying the composition identifiers by counting the nanoparticle-associated barcode sequences;
[0009] wherein the biologically active agents can edit a target nucleic acid by performing biological activity when delivered to the cells in vitro or delivered to the cell of the subject.
[0010] In some embodiments, the target nucleic acid is in the genome. In some embodiments, the target nucleic acid is a DNA. In some embodiments, the target nucleic acid is an RNA.
[0011] In some embodiments, the method further comprises isolating genomic DNA of tissues or cells and amplifying the genomic fragment before identifying the identifiers.
[0012] In some embodiments, the method does not comprise any steps of sorting cells.
[0013] In some embodiments, the count of vehicle-associated barcode sequences is determined by sequencing barcodes.
[0014] In some embodiments, the multiple delivery vehicles are administered to the cells or to the subject simultaneously.
[0015] In some embodiments, the biologically active agents comprise one or more nucleic acids. In some embodiments, the nucleic acids comprise RNAs, DNAs, or the combinations thereof. In some embodiments, the biologically active agents comprise one or more RNAs. In some embodiments, the RNA component comprises a modified RNA. In some embodiments, the RNA component comprises a sequence encoding RNA-guided DNA-binding agent. In some embodiments, the RNA component comprises mRNA. In some embodiments, the RNA component comprises a Cas nuclease mRNA. In some embodiments, the RNA component comprises a Class 2 Cas nuclease mRNA. In some embodiments, the RNA component comprises a mRNA encoding Cas9, Cpf1, c2c2, cas12i, cas12f, cas12b, cas12c, cas12d, cas12e, cas12g, cas12j, or cas12k nuclease. In some embodiments, the RNA component comprises one or more gRNA nucleic acids. In some embodiments, the RNA component comprises one or more Cas nuclease mRNA and one or more gRNA. In some embodiments, the RNA component comprises a Cas nuclease mRNA and a gRNA. In some embodiments, the gRNA nucleic acid is or encodes a dual-guide RNA (dgRNA) . In some embodiments, the gRNA nucleic acid is or encodes a single-guide RNA (sgRNA) . In some embodiments, the gRNA is a modified gRNA.
[0016] In some embodiments, the biologically active agents comprise component capable of altering (e.g. inserting) the target site by partial or complete sequence of the identifier. In some embodiments, the biologically active agents comprise nucleases, integrases, transposases or reverse transcriptases or nucleic acid encoding such nucleases, integrases, transposases or reverse transcriptases. In some embodiments, the nucleases herein include CRISPR / Cas, ZFN, Meganucleases, TALEN. In some embodiments, the biologically active agents comprise RNA-guided DNA-binding agent or nucleic acid encoding the RNA-guided DNA-binding agents. In some embodiments, the RNA-guided DNA-binding agents comprise Cas nuclease, preferably, the Cas nuclease is SpCas9 or SaCas9.
[0017] In some embodiments, the biologically active agents comprise gRNA, preferably, the gRNA is modified gRNA.
[0018] In some embodiments, the delivery vehicles comprise lipid nanoparticles, virus derived vehicles, exosomes, extracellular contractile injection systems, bacterial derived delivery systems, cell derived delivery systems or combinations thereof. In some embodiments, the delivery vehicles comprise LNP. In some embodiments, the delivery vehicles comprise AAV or LV. In some embodiments, the delivery vehicles comprise PLTS or eCIS. In some embodiments, the delivery vehicles comprise engineered erythrocytes. In some embodiments, the delivery vehicles comprise engineered Photorhabdus virulence cassette (PVC) , In some embodiments, the delivery vehicles comprise endogenous virus protein particles.
[0019] In some embodiments, the delivery vehicles comprise lipid nanoparticles. In some embodiments, the delivery vehicles comprise an ionizable lipid, a non-ionizable lipid and a PEG lipid. In some embodiments, the non-ionizable lipid comprises one or more neutral lipid. In some embodiments, the non-ionizable lipid comprises cholesterol. In some embodiments, the delivery vehicles are LNP, preferably, each LNP comprises an ionizable lipid, a neutral lipid, a cholesterol and / or a PEG lipid.
[0020] In some embodiments, the structure of the ionizable lipids, the molar amount of PEG lipids, the structure of PEG lipids, the molar amount of neutral lipids, the structure of neutral lipids and / or the molar amount of cholesterol, in the delivery vehicle are varied among the delivery vehicles.
[0021] In some embodiments, the identifiers comprise one or more sequences of nucleic acid barcodes. In some embodiments, the nucleic acid barcodes are designed to alter (e.g. insert into) the target genes; In some embodiments, the nucleic acid barcodes are designed to insert into the target genes; In some embodiments, the nucleic acid barcodes comprise sequence to identify the composition of the delivery vehicle. In some embodiments, the nucleic acid barcodes are nucleic acid barcode oligonucleotides. In some embodiments, the nucleic acid barcodes are RNA barcode oligonucleotides. In some embodiments, the nucleic acid barcodes are single-stranded nucleic acids. In some embodiments, the nucleic acid barcodes are double-stranded nucleic acids.
[0022] In some embodiments, delivery vehicles do not contain any components unrelated to gene alteration (e.g., insertion) . In some embodiments, delivery vehicles may contain components unrelated to gene alteration (e.g., insertion) , but do not solely rely on these components for characterizing or identifying.
[0023] In some embodiments, the subject is non-human mammal. In some embodiments, the non-human mammal comprises rat, mice or non-human primate. In some embodiments, the method is a high-throughput method. In some embodiments, at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 200 different delivery vehicles are assayed in the method. In some embodiments, greater than 60 different delivery vehicles are assayed. In some embodiments, greater than 100 different delivery vehicles are assayed. In some embodiments, greater than 200 different delivery vehicles are assayed.
[0024] In some embodiments, the tissues or cells herein are from liver, lung, spleen, heart, kidney, brain, bone marrow, lymph nodes, blood, T-cells, stem cells or ovary or testis and so on.
[0025] In some embodiments, the method further comprises one or more the following steps: (i) dividing the number of sequencing reads of one barcode delivered by a single vehicle by the total amount of reads from all barcodes delivered by all vehicle in a specific cell or tissue; (ii) dividing the number of sequencing reads of the same barcode (utilized in (i) ) by the total amount of reads from all barcodes of all vehicles in the non-injected vehicle pool; (iii) dividing the results from (i) by the results from (ii) .
[0026] In another embodiments, this disclosure provides a composition comprising: one or more empty delivery vehicles, one or more nucleic acid barcodes, and one or more biologically active agents; wherein the biologically active agents can edit genome by performing a biological activity when delivered to the cells in vitro or delivered to the cell of the subject.
[0027] In some embodiments, the delivery vehicle is a lipid nanoparticle. In some embodiments, the biologically active agents comprise one or more nucleic acids. In some embodiments, the nucleic acids comprise sequences encoding RNA-guided DNA-binding agent. In some embodiments, the nucleic acid comprises mRNA. In some embodiments, nucleic acid comprises a Cas nuclease mRNA. In some embodiments, the Cas nuclease mRNA comprises a Class 2 Cas nuclease mRNA. In some embodiments, the nucleic acid comprises a mRNA encoding Cas9, Cpf1, c2c2, cas12i, cas12f, cas12b, cas12c, cas12d, cas12e, cas12g, cas12j, or cas12k nuclease. In some embodiments, the nucleic acid comprises a gRNA nucleic acid. In some embodiments, the nucleic acid comprises one or more Cas nuclease mRNAs and one or more gRNAs. In some embodiments, the nucleic acid comprises a Cas nuclease mRNA and a gRNA. In some embodiments, the gRNA nucleic acid is or encodes a dual-guide RNA (dgRNA) or a single-guide RNA (sgRNA) . In some embodiments, the gRNA is a modified gRNA.
[0028] In some embodiments, the delivery vehicles comprise one or more lipid nanoparticles. In some embodiments, the delivery vehicles comprise one or more ionizable lipids, one or more non-ionizable lipid, and / or PEG lipids. In some embodiments, the non-ionizable lipid comprises one or more neutral lipid. In some embodiments, the non-ionizable lipid comprises cholesterol.
[0029] In some embodiments, the ionizable lipids, the molar amount of PEG lipids, the structure of PEG lipids, the molar amount of neutral lipids, the structure of neutral lipids and the molar amount of cholesterol, in the delivery vehicle are varied among the delivery vehicles.
[0030] In some embodiments, the nucleic acid barcodes are barcode oligonucleotides. In some embodiments, the nucleic acid barcodes are RNA barcode oligonucleotide. In some embodiments, the nucleic acid barcodes are single-stranded nucleic acids. In some embodiments, the nucleic acid barcodes are double-stranded nucleic acids.
[0031] In another embodiments, this invention provides nucleic acid barcode according to the following formula: R1-R2-R3-R4-R5, wherein R1, R2, R3, R4 and R5 are independently selected from universal sequence, random nucleotide sequence, or barcode sequence.
[0032] In some embodiments, R1 represents barcode sequence; R2 represents universal sequence; R3 represents random nucleotide sequence; R4 represents second random nucleotide sequence; R5 represents second universal sequence. In some embodiments, R1 represents universal sequence; R2 represents barcode sequence; R3 represents random nucleotide sequence; R4 represents second random nucleotide sequence; R5 represents second universal sequence. In some embodiments, R1 represents universal sequence; R2 represents random nucleotide sequence; R3 represents second random nucleotide sequence; R4 represents second universal sequence; R5 represents barcode sequence. In some embodiments, R1 represents barcode sequence, R2 represents universal sequence; R3 represents random nucleotide sequence; R4 represents second universal sequence; R5 represents second random nucleotide sequence. In some embodiments, R1 represents random nucleotide sequence, R2 represents universal sequence; R3 represents second random nucleotide sequence; R4 represents second universal sequence; R5 represents barcode sequence. In some embodiments, R1 represents universal sequence; R2 represents a random nucleotide sequence; R3 represents barcode sequence; R4 represents a second random nucleotide sequence; R5 represents a second universal sequence.
[0033] In some embodiments, the nucleic acid barcodes are DNA barcode oligonucleotides. In some embodiments, the nucleic acid barcodes are RNA barcode oligonucleotides. In some embodiments, the nucleic acid barcodes are single-stranded nucleic acids. In some embodiments, the nucleic acid barcodes are double-stranded nucleic acids.
[0034] In some embodiments, the nucleic acid barcodes are 5-100 nucleotides in length; In some embodiments, the nucleic acid barcodes are 10-70 nucleotides in length; In some embodiments, the nucleic acid barcodes are 20-60 nucleotides in length; In some embodiments, the nucleic acid barcodes are 20-50 nucleotides in length; In some embodiments, the nucleic acid barcodes are 30-50 nucleotides in length. In some embodiments, the nucleic acid barcodes are 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length. In some embodiments, the nucleic acid barcodes are 30, 31, 32, 33, 34, 35 nucleotides in length.
[0035] In some embodiments, the random nucleotide sequence contains 0 to 20 nucleotides in length. In some embodiments, the nucleic acid barcode is modified. In some embodiments, the universal sequence is modified. In some embodiments, the random nucleotide sequence is modified. In some embodiments, the barcode sequence is modified.
[0036] In some embodiments, the result of editing genome leads to the partial or complete sequence of nucleic acid barcodes being inserted into the target gene.
[0037] This disclosure also provides a nucleic acid barcode, wherein the nucleic acid barcode comprises a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%or 100%sequence identity to any one of SEQ ID NOs: 1-341. In some embodiments, the nucleic acid barcode comprises a sequence having at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that are identical to any one of the sequences selected from SEQ ID NOs: 1-341.Brief description of the drawings
[0038] Figure 1 (Fig 1) : Nucleic acid barcoded nanoparticles for high throughput in vivo nanoparticle delivery. A: Lipid nanoparticles (LNPs) were formulated to carry Cas9 mRNA, sgRNA and nucleic acid barcodes. B: Stable LNPs were pooled together and administered to rodent or non-human primate. Cells or tissues were deep sequenced to quantify the relative delivery of all the LNPs simultaneously.
[0039] Figure 2 (Fig 2) : The indel frequency in HepG2 using different doses of Lipofectamine RNAiMAX and same doses of barcode.
[0040] Figure 3 (Fig 3) : The normalized barcode readouts in HepG2 using different doses of Lipofectamine RNAiMAX and same doses of barcode.
[0041] Figure 4 (Fig 4) : Correlation analysis between normalized barcode readouts and lipofectamine dose.
[0042] Figure 5 (Fig 5) : The indel frequency in HepG2 using same dose of Lipofectamine RNAiMAX and different doses of barcode.
[0043] Figure 6 (Fig 6) : The normalized barcode readouts in HepG2 using same dose of Lipofectamine RNAiMAX and different doses of barcode.
[0044] Figure 7 (Fig 7) : Correlation analysis between normalized barcode readouts and barcode dose.
[0045] Figure 8 (Fig 8) : Indel frequency biodistribution within the 5 tissues examined by normalized barcode readouts.
[0046] Figure 9 (Fig 9) : Heatmap of normalized delivery for all 68 LNPs in rat.
[0047] Figure 10 (Fig 10) : Typical representative at each level of LNP delivery efficiency (high, middle and low) to the liver, which were quantified by normalized barcode readouts from rats.
[0048] Figure 11 (Fig 11) : The barcode efficiency in HepG2 using same dose of Lipofectamine RNAiMAX and different barcodes.
[0049] Figure 12 (Fig 12) : The barcode efficiency in cynomolgus liver using different LNPs contained same RNA and different barcodes.
[0050] Figure 13 (Fig 13) : The barcode efficiency in cynomolgus liver using different LNPs contained same RNA and different lipids.
[0051] Figure 14 (Fig 14) : The indel frequency in cynomolgus liver using single LNP contained the lipid 32
[0052] Figure 15 (Fig 15) : The reduction in serum target protein concentration as a proportion of baseline in cynomolgus monkeys receiving intravenous administration of LNP100 at doses of 3.0 mg / kg (total RNA / body weight) .
[0053] Figure 16 (Fig 16) : The barcode efficiency in mice lung using different LNPs contained same RNA and different lipids.
[0054] Figure 17 (Fig 17) : The barcode efficiency in cynomolgus lung, spleen and heart using different LNPs contained same RNA and different lipids.
[0055] Detailed description of the preferred embodiment
[0056] It is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.
[0057] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0058] It should be understood that any part, claims or embodiments, or any features in such part, claims or embodiments of the present disclosure may be freely combined, whether it is any part, claims or embodiments, or any features in such part, claims or embodiments in the claims or any part or embodiments in the description. The combined part, claims or embodiments are all included in this disclosure.
[0059] 1. Method
[0060] A method for characterizing delivery vehicles for delivery of an agent is disclosed in this invention. In vivo or in vitro delivery is all included in this disclosure. In some embodiments, the methods of the present invention may be used to characterize any factors that affect delivery or function of the delivery system or cargos; such as composition of the delivery system, amount, manufacturing company, composition of the delivered cargo, amount, etc. In some embodiments, the methods of the present invention are used to characterize factors influencing the delivery system; in another embodiments, the methods of the present invention are used to characterize factors affecting the activity of the cargo.
[0061] In some embodiments, the method comprising:
[0062] (a) formulating multiple delivery vehicles having different compositions, wherein each different delivery vehicle comprises: i) one or more biologically active agents, and ii) one or more identifiers that identify the composition of the delivery vehicle;
[0063] (b) administering the multiple delivery vehicles to cells or to a subject; and
[0064] (c) identifying the identifiers by counting the vehicle-associated barcode sequences;
[0065] wherein the biologically active agents can edit a target nucleic acid by performing biological activity when delivered to the cells in vitro or delivered to the cells of the subject.
[0066] In some embodiments, the method further comprises isolating genomic DNA or RNA of tissues or cells, and amplifying the genomic fragment before identifying the identifiers.
[0067] Any tissue or cell that can be used to demonstrate tissue or cell-targeting specificity in a subject is included in the disclosure. In some embodiments, the tissues or cells are from liver, lung, spleen, heart, kidney, brain, bone marrow, lymph nodes, blood, T-cells, stem cells or ovary / tesis and so on.
[0068] Any counting method from the prior art is included within the present invention. In some embodiments, counting is performed by sequencing.
[0069] "Vehicle-associated barcode sequences" refer to sequences used to characterize the corresponding "vehicle. "
[0070] In some embodiments, the biologically active agents comprise an RNA-guided DNA-binding proteins, such as a CRISPR / Cas effector, or the polynucleotides encoding such proteins. In some embodiments, the identifier is designed to be a nucleic acid sequence that is capble of altering (e.g. inserting into) the target site. The target site in this disclosure can be a DNA or an RNA. In some embodiments, any biologically active agents (such as nucleases, integrases, transposases, reverse transcriptases, etc. ) capable of altering the target site with the identifier are included within the present disclosure. In some embodiments, the nucleases herein include CRISPR / Cas, ZFN, Meganucleases, TALEN, etc. In some embodiments, the biologically active agents are proteins (e.g. nucleases, integrases, transposases, reverse transcriptases herein) , or polynucleotides encoding such proteins.
[0071] The nucleic acid barcodes or the identifiers are (or are designed to be) capable of “altering the target site / sequence” , “altering the target gene” , “inserting into the target site / sequence” , “inserting into the target gene” , or to “alter the target site / sequence” , “alter the target gene” , “insert into the target site / sequence” , “insert into the target gene” , or other similar expressions, should be understood to alter or insert into or near the target site with partial or complete sequences of such nucleic acid barcodes or identifiers.
[0072] In some embodiments, the biologically active agents can edit a target nucleic acid by performing a biological activity when delivered to the cells in vitro or delivered to the cell of the subject. In some embodiments, the target nucleic acid is in the genome. The “genome” refers to the complete set of genes or genetic material present in a cell, tissue or organism. In some embodiments, the genome comprises a DNA. In some embodiments, the genome comprises an RNA (e.g., an mRNA) .
[0073] In some embodiments, the method further comprises one or more the following steps: (d) dividing the number of sequencing reads of one barcode delivered by a single vehicle by the total amount of reads from all barcodes delivered by all vehicle in a specific cell or tissue; (e) dividing the number of sequencing reads of the same barcode (utilized in (d) ) by the total amount of reads from all barcodes of all vehicles in the non-injected vehicle pool; (f) dividing the results from (d) by the results from (e) . By using this quantification method, the delivery of different vehicles within the same organ can be compared, but the delivery of the same vehicles across different organs cannot be compared.
[0074] 2. Delivery Vehicles
[0075] As understood from the context, in some embodiments, “vehicles” , “particles” , or similar terms are used interchangeably in the present disclosure. Delivery systems having any characteristics can be characterized by the methods described in the present disclosure. For example, such characteristics comprises composition, amount, preparation process, parameters (e.g., particle size, charge, PDI etc. ) .
[0076] Any delivery vehicles capable of delivering the cargo into a cell is within the scope of this disclosure. The “empty delivery vehicles” or similar terms, means the composition of the vehicles and do not indicate any relationship with other components of the vehicles. Regardless of whether they are carrying cargo or not, as far as that part of the delivery system is concerned, it can be referred to as "empty delivery vehicles. " For instance, a vehicle wrapping cargo in this disclosure could be represented as an "empty delivery vehicle" and a "Cargo. " A vehicle with cargo adsorbed onto its surface can also be represented as an "empty delivery vehicle" and a "cargo. " A vehicle with cargo separated from it can also be represented as an "empty delivery vehicle" and a "cargo. " In some embodiments, the cargo delivered can edit a target nucleic acid by performing a biological activity.
[0077] The delivery vehicles may be provided as particles compositions. In some embodiments, the delivery vehicles comprise lipid nanoparticles, virus derived delivery system, virus like particles, virus-like protein derived delivery system, exosomes, extracellular contractile injection systems, bacterial derived delivery system, cell derived delivery system or combinations thereof. In some embodiments, the delivery vehicles comprise LNP. In some embodiments, the delivery vehicles comprise AAV or LV. In some embodiments, the delivery vehicles comprise PLTS or eCIS. In some embodiments, the delivery vehicles comprise engineered erythrocytes. In some embodiments, the delivery vehicles comprise engineered Photorhabdus virulence cassette (PVC) , In some embodiments, the delivery vehicles comprise endogenous virus protein particles.
[0078] Suitable delivery vehicles or vectors include viral delivery vehicles or vectors (e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol Vis Sci 35: 25432549, 1994; Borras et al., Gene Ther 6: 515524, 1999; Li and Davidson, PNAS 92: 77007704, 1995; Sakamoto et al., H Gene Ther 5: 10881097, 1999; WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655) ; adeno-associated virus (AAV) (see, e.g., Ali et al., Hum Gene Ther 9: 81 86, 1998, Flannery et al., PNAS 94: 69166921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38: 2857 2863, 1997; Jomary et al., Gene Ther 4: 683690, 1997, Rolling et al., Hum Gene Ther 10: 641648, 1999; Ali et al., Hum Mol Genet 5: 591594, 1996; Srivastava in WO 93 / 09239, Samulski et al., J. Vir. (1989) 63: 3822-3828; Mendelson et al., Virol. (1988) 166: 154-165; and Flotte et al., PNAS (1993) 90: 10613-10617) ; SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshi et al., PNAS 94: 1031923, 1997; Takahashi et al., J Virol 73: 78127816, 1999) ; a retroviral vector (e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus) ; and the like. In some cases, a recombinant expression vector of the present disclosure is a recombinant adeno-associated virus (AAV) vector. In some cases, a recombinant expression vector of the present disclosure is a recombinant lentivirus vector. In some cases, a recombinant expression vector of the present disclosure is a recombinant retroviral vector.
[0079] In some embodiments, the particles may be, for example, microspheres (including unilamellar and multilamellar vesicles, e.g., "liposomes" -lamellar phase lipid bilayers that, in some embodiments are substantially spherical, and, in more particular embodiments can comprise an aqueous core, e.g., comprising a substantial portion of RNA molecules) , a dispersed phase in an emulsion, micelles, or an internal phase in a suspension.
[0080] According to exemplary embodiments, the particles may be comprised of a cationic lipid or ionizable lipid (such as compound described in prior art) , cholesterol, phospholipid (such as 1, 2-Distearoylsn-glycero-3-phosphocholine) , PEG derivative (such as DMG-PEG) ; at various mol: mol ratios.
[0081] In some embodiments, the composition is an LNP composition. In some embodiments, the lipid component comprises an ionizable lipid and a PEG lipid. In some embodiments, the non-cationic lipid is a neutral lipid.
[0082] “Neutral lipids” suitable for use in a lipid composition of the invention include, for example, a variety of neutral, uncharged or zwitterionic lipids. Examples of neutral phospholipids suitable for use in the present invention include, but are not limited to: 5-heptadecylbenzene-1, 3-diol (resorcinol) , dipalmitoylphosphatidylcholine (DPPC) , distearoylphosphatidylcholine (DSPC) , phosphocholine (DOPC) , dimyristoylphosphatidylcholine (DMPC) , phosphatidylcholine (PLPC) , 1, 2-distearoyl-sn-glycero-3-phosphocholine (DAPC) , phosphatidylethanolamine (PE) , egg phosphatidylcholine (EPC) , dilauryloylphosphatidylcholine (DLPC) , dimyristoylphosphatidylcholine (DMPC) , 1-myristoyl-2-palmitoyl phosphatidylcholine (MPPC) , 1-palmitoyl-2-myristoyl phosphatidylcholine (PMPC) , 1-palmitoyl-2-stearoyl phosphatidylcholine (PSPC) , 1, 2-diarachidoyl-sn-glycero-3- phosphocholine (DBPC) , 1-stearoyl-2- palmitoyl phosphatidylcholine (SPPC) , 1, 2-dieicosenoyl-sn-glycero -3-phosphocholine (DEPC) , palmitoyloleoyl phosphatidylcholine (POPC) , Iysophosphatidyl choline, dioleoyl phosphatidylethanolamine (DOPE) , dilinoleoylphosphatidylcholine distearoylphophatidylethanolamine (DSPE) , dimyristoyl phosphatidylethanolamine (DMPE) , dipalmitoyl phosphatidylethanolamine (DPPE) , palmitoyloleoyl phosphatidylethanolamine (POPE) , Iysophosphatidylethanolamine and combinations thereof. In one embodiment, the neutral phospholipid is selected from the group consisting of distearoylphosphatidylcholine (DSPC) and dimyristoyl phosphatidyl ethanolamine (DMPE) .
[0083] In some embodiments, the PEG derivatives may be conjugated to one or more additional molecules, such as, a lipid. In some embodiments, the PEG derivative is selected from, but not limited to: PEG-DMG, 3-N- (-methoxy poly (ethylene glycol) 2000) carbamoyl-1, 2-dimyrisyl glycerol, PEG-CDMA, 3-N- (-methoxy poly ( ethylene glycol) 2000) carbamoyl-1, 2-dimyristyloxy-propylamine; PEG-CDSA, 3-N (-methoxy poly (ethylene glycol) 2000) carbamoyl-1, 2-distearyloxy-propylamine, DSPE-PEG, PEG-maleimide, DSPE-PEG-maleimide, or combinations thereof. Each possibility represents a separate embodiment of the present invention.
[0084] In some embodiments, the particles are nanoparticles. In some embodiments, the particles (including the nucleic acid encapsulated within) and the targeting moiety on the surface particles have a particle size (diameter) in the range of about 10 to about 500 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 10 to about 350 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 250 nm.In some embodiments, the particles have a particle size (diameter) in the range of about 10 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 20 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 75 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 90 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 100 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 120 to about 200 nm.In some embodiments, the particles have a particle size (diameter) in the range of about 150 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 150 nm. In some embodiments, the particles have a particle size (diameter) in the range of over about 10 nm. In some embodiments, the particles have a particle size (diameter) of over about 20 nm. In some embodiments, the particles have a particle size (diameter) of over about 30 nm. In some embodiments, the particles have a particle size (diameter) of over about 40 nm.In some embodiments, the particles have a particle size (diameter) of over about 50 nm. In some embodiments, the particles have a particle size (diameter) of over about 60 nm. In some embodiments, the particles have a particle size (diameter) of over about 70 nm. In some embodiments, the particles have a particle size (diameter) of over about 80 nm. In some embodiments, the particles have a particle size (diameter) of over about 90 nm. In some embodiments, the particles have a particle size (diameter) of over about 100 nm. In some embodiments, the particles have a particle size (diameter) of over about 200 nm. In some embodiments, the particles have a particle size (diameter) of not more than about 500 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 5 to about 200 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 50 to about 60 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 55 to about 58 nm. In some embodiments, the size is a hydrodynamic diameter.
[0085] As used herein, the “polydispersity index” or “PDI” is a ratio that describes the homogeneity of the particle size distribution of a system. A small value, e.g., less than 0.3, indicates a narrow particle size distribution. In some embodiments, the polydispersity index may be less than 0.1. In some embodiments, the LNPs disclosed herein have a polydispersity index (PDI) that may range from about 0.005 to about 0.75. In some embodiments, the LNP have a PDI that may range from about 0.01 to about 0.5. In some embodiments, the LNP have a PDI that may range from about zero to about 0.4. In some embodiments, the LNP have a PDI that may range from about zero to about 0.35. In some embodiments, the LNP have a PDI that may range from about zero to about 0.35. In some embodiments, the LNP PDI may range from about zero to about 0.3. In some embodiments, the LNP have a PDI that may range from about zero to about 0.25. In some embodiments, the LNP PDI may range from about zero to about 0.2. In some embodiments, the LNP have a PDI that may be less than about 0.08, 0.1, 0.15, 0.2, or 0.4.
[0086] In some embodiments, LNPs are formed by mixing an aqueous RNA solution with an organic solvent-based lipid solution. Suitable solutions or solvents include or may contain: water, PBS, Tris buffer, NaCl, citrate buffer, acetate buffer, ethanol, chloroform, diethylether, cyclohexane, tetrahydrofuran, methanol, isopropanol. For example, the organic solvent may be 100%ethanol. A pharmaceutically acceptable buffer, e.g., for in vivo administration of LNPs, may be used. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 6.5. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 7.0. In certain embodiments, the composition has a pH ranging from about 7.2 to about 7.7. In additional embodiments, the composition has a pH ranging from about 7.3 to about 7.7 or ranging from about 7.4 to about 7.6. In further embodiments, the composition has a pH of about 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7. The pH of a composition may be measured with a micro pH probe. In certain embodiments, a cryoprotectant is included in the composition. Non-limiting examples of cryoprotectants include sucrose, trehalose, glycerol, DMSO, and ethylene glycol. Exemplary compositions may include up to 10%cryoprotectant, such as, for example, sucrose. In certain embodiments, the composition may comprise tris saline sucrose (TSS) . In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%cryoprotectant. In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%sucrose. In some embodiments, the LNP composition may include a buffer. In some embodiments, the buffer may comprise a phosphate buffer (PBS) , a Tris buffer, a citrate buffer, and mixtures thereof. In certain exemplary embodiments, the buffer comprises NaCl. In certain embodiments, the buffer lacks NaCl. Exemplary amounts of NaCl may range from about 20 mM to about 45 mM. Exemplary amounts of NaCl may range from about 40 mM to about 50 mM.In some embodiments, the amount of NaCl is about 45 mM. In some embodiments, the buffer is a Tris buffer. Exemplary amounts of Tris may range from about 20 mM to about 60 mM. Exemplary amounts of Tris may range from about 40 mM to about 60 mM. In some embodiments, the amount of Tris is about 50 mM. In some embodiments, the buffer comprises NaCl and Tris. Certain exemplary embodiments of the LNP compositions contain 5%sucrose and 45 mM NaCl in Tris buffer. In other exemplary embodiments, compositions contain sucrose in an amount of about 5%w / v, about 45 mM NaCl, and about 50 mM Tris at pH 7.5. The salt, buffer, and cryoprotectant amounts may be varied such that the osmolality of the overall composition is maintained. Identifiers
[0087] In some embodiments, this invention provides one or more identifiers. In some embodiments, the identifiers are designed to alter the target genes. In some embodiments, the identifiers are designed to insert into the target genes. In some embodiments, the identifier comprises one or more sequences of nucleic acid barcodes. The nucleic acid barcodes can be rationally designed to make the nucleic acid including the sequence of the barcodes successfully insert the genome. In some embodiments, the nucleic acid barcodes are designed to alter the target genes. In some embodiments, the nucleic acid barcodes are designed to insert into the target genes. In some embodiments, the insertion into the target genes is partial or complete sequence of the identifier.
[0088] As used herein, the term "nucleic acid barcode" refers to an oligonucleotide having a nucleic acid sequence that contains a series of nucleotides ( "barcode sequence" ) unique to the barcode and optionally a series ofnucleotides common to other barcodes. The common nucleotides can be used, for example, to isolate and sequence the barcode. Therefore, in some cases, the barcode sequence is flanked by upstream and / or downstream primer sites, such as, for example, universal primer sites. The polynucleotide can include a DNA nucleotide, an RNA nucleotide, or a combination thereof. Each delivery vehicle formulation is paired with its own unique nucleic acid barcode. The unique nucleic acid barcode is paired to the chemical composition of the delivery vehicle formulation and by sequencing the nucleic acid barcode, one can identify the specific chemical composition used to produce that specific vehicle delivery formulation.
[0089] In some embodiments, the nucleic acid barcode can contain 5 to 250 nucleotides in length, about 5 to about 200 nucleotides in length, about 5 to about 150 nucleotides in length, about 5 to about 90 nucleotides in length, about 5 to about 80 nucleotides in length, about 5 to about 70 nucleotides in length, about 5 to about 60 nucleotides in length, about 5 to about 50 nucleotides in length, about 5 to about 45 nucleotides in length, about 5 to about 40 nucleotides. In some embodiments, the nucleic acid barcodes are 5-100 nucleotides in length; In some embodiments, the nucleic acid barcodes are 10-70 nucleotides in length; In some embodiments, the nucleic acid barcodes are 20-60 nucleotides in length; In some embodiments, the nucleic acid barcodes are 20-50 nucleotides in length; In some embodiments, the nucleic acid barcodes are 30-50 nucleotides in length. In some embodiments, the nucleic acid barcodes are 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length. In some embodiments, the nucleic acid barcodes are 30, 31, 32, 33, 34, 35 nucleotides in length.
[0090] The nucleic acid barcodes can be covalently or non-covalently attached to the disclosed delivery vehicle. In some embodiments, the nucleic acid barcode is encapsulated by the delivery vehicle.
[0091] In some embodiments, the random nucleotide sequence contains 0 to 20 nucleotides in length. In some embodiments, the random nucleotide sequence contains 5 to15 nucleotides in length. In some embodiments, the random nucleotide sequence contains 8 to12 nucleotides in length. In some embodiments, the random nucleotide sequence contains 10 nucleotides in length.
[0092] In some embodiments, nucleic acid sequences of the barcodes are modified, In certain embodiments. Modified nucleosides, nucleotides or oligonucleotide can be present in the RNA or DNA, for example the nucleic acid barcodes comprising one or more modified nucleosides or nucleotides, for example, is called a “modified” RNA or DNA to describe the presence of one or more non-naturally and / or naturally occurring components or configurations that are used instead of or in addition to the canonical A, G, C, T, and U residues. In some embodiments, a modified nucleic acid synthesized with a non-canonical nucleoside or nucleotide, here called “modified. ” In some embodiments, the both the double strands are modified. In some embodiments, only one strand of the double strands is modified.
[0093] Modified nucleosides or nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and / or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage (an exemplary backbone modification) ; (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2′hydroxyl on the ribose sugar (an exemplary sugar modification) ; (iii) wholesale replacement of the phosphate moiety with “dephospho” linkers (an exemplary backbone modification) ; (iv) modification or replacement of a naturally occurring nucleobase, including with a non-canonical nucleobase (an exemplary base modification) ; (v) replacement or modification of the ribose-phosphate backbone (an exemplary backbone modification) ; (vi) modification of the 3′ end or 5′ end of the polynucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, cap or linker (such 3′ or 5′ cap modifications may comprise a sugar and / or backbone modification) ; and (vii) modification or replacement of the sugar (an exemplary sugar modification) .
[0094] In some embodiments, the sequence comprises phosphorylation at the 5' end (5'-phospht or 5'-phosp) ; In some embodiments, the sequence comprises phosphorylation at the 3' end (3'-phospht or 3'-phosp) ; In some embodiments, the sequence comprises phosphorothioate linkage between the nucleosides or nucleotides of the sequences. In some embodiments, the sequence comprises phosphorothioate linkage at 3' end. In some embodiment, the sequence comprises phosphorothioate linkage between the last 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides or nucleotides of the sequences. In some embodiments, the sequence comprises phosphorothioate linkage between the first 1-20 nucleosides or nucleotides of the sequences; In some embodiments, the sequence comprises phosphorothioate linkage between the first 2-10 nucleosides or nucleotides of the sequences; In some embodiments, the sequence comprises phosphorothioate linkage between the first 3-8 nucleosides or nucleotides of the sequences; In some embodiments, the sequence comprises phosphorothioate linkage between the last 1-20 nucleosides or nucleotides of the sequences; In some embodiments, the sequence comprises phosphorothioate linkage between the last 2-10 nucleosides or nucleotides of the sequences; In some embodiments, the sequence comprises phosphorothioate linkage between the last 3-8 nucleosides or nucleotides of the sequences; Certain embodiments comprise phosphorylation at 5' end and linkage between the nucleosides or nucleotides of the sequences. Certain embodiments comprise phosphorylation at 5' end and 1-5 phosphorothioate linkage of the sequences. In some embodiments, the sequence comprises phosphorylation at 5' end and three phosphorothioate linkages of the sequences. In some embodiments, the sequence comprises phosphorylation at 5' end and three phosphorothioate linkages of the last four nucleotides.
[0095] The phosphorylation at the 5’ end (5’-phospht) , or the phosphorylation at the 3’ end (3’-phospht) , can be described as followings:
[0096] In some embodiments, phosphorylation is indicated by ′ / phosp / ′, and the position of ′ / phosp / ′ denotes the site of phosphorylation. For example, ′ / 5phosp / CGTCCAGTTACGACGTAGGTCGACGAGTCGC′ represents a phosphorylated 5′-end. ′*′ represents a phosphorothioate linkage, as defined elsewhere in this disclosure, such as ′ / phosp / CGTCCAGTTACGACGTAGGTCGACGAGT*C*G*C′ indicating both a 5′-end phosphorylation and phosphorothioate linkages between the last four nucleotides.
[0097] In other embodiments, the modifications in this invention comprise modified phosphate groups include, phosphorylation, phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral. The stereogenic phosphorous atom can possess either the “R” configuration (herein Rp) or the “S” configuration (herein Sp) . The backbone can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside) , with nitrogen (bridged phosphoroamidates) , sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates) . The replacement can occur at either linking oxygen or at both of the linking oxygens. The phosphate group can be replaced by non-phosphorus containing connectors in certain backbone modifications. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.
[0098] The nucleic acid barcode in the compositions and methods disclosed herein may be used to alter (e.g., insert) a nucleic acid sequence at or near a target site for an RNA-guided DNA-binding protein such as a Cas nuclease, e.g., a Class 2 Cas nuclease. In some embodiments, the methods comprise introducing a template to the cell. In some embodiments, single-stranded nucleic acid (s) or may be provided; In some embodiments, double-stranded nucleic acid (s) may be provided. In some embodiments, the nucleic acid sequence (s) to be altered or inserted is / are the target nucleic acid sequence of the genome. In other embodiments, two or more nucleic acid (s) may be provided such that editing may occur at two or more target sites. For example, different nucleic acid (s) may be provided to edit a single gene in a cell, or two different genes in a cell.
[0099] In some embodiments, the nucleic acid barcode (s) may be used in homologous recombination. In some embodiments, the homologous recombination may result in the integration of the nucleic acid barcode (s) sequence or a portion of the nucleic acid (s) sequence into the target nucleic acid molecule. In other embodiments, the nucleic acid (s) may be used in homology-directed repair, which involves DNA strand invasion at the site of the cleavage in the nucleic acid. In some embodiments, the homology-directed repair may result in including the nucleic acid (s) sequence in the edited target nucleic acid molecule. In yet other embodiments, the nucleic acid (s) may be used in gene editing mediated by non-homologous end joining. In some embodiments, the nucleic acid (s) sequence has no similarity to the nucleic acid sequence near the cleavage site. In some embodiments, the nucleic acid (s) or a portion of the nucleic acid (s) sequence is incorporated. In some embodiments, the nucleic acid (s) includes flanking inverted terminal repeat (ITR) sequences.
[0100] The barcodes may be single-strand or double-strand types. If the double-stranded types are used, the double-stranded nucleic acids consist of one strand of the barcodes and the complementary strand. If the single-strand types are used, the nucleic acids only have one strand of the barcode. The examples of one strand of the barcodes used in this invention are shown in the following table 1:
[0101] Table 1: Exemplary barcode sequences in this disclosure
[0102] In some embodiments, the dosage of the identifiers is optimized to improve editing efficiency. In some embodiments, the mass ratio of the dosage of identifier to that of total RNA is 1: 5-1: 200. In some embodiments, the mass ratio of the dosage of identifier to that of total RNA is 1: 5, 1: 10, 1: 15, 1: 20, 1: 25, 1: 30, 1: 35, 1: 40, 1: 45, 1: 50, 1: 55, 1: 60, 1: 65, 1: 70, 1: 75, 1: 80, 1: 85, 1: 90, 1: 95, 1: 100, 1: 105, 1: 110, 1: 115, 1: 120, 1: 125, 1: 130, 1: 135, 1: 140, 1: 145, 1: 150, 1: 155, 1: 160, 1: 165, 1: 170, 1: 175, 1: 180, 1: 185, 1: 190, 1: 195 or 1: 200.
[0103] Biologically Active Agents
[0104] As used herein, "biologically active agents" is used to refer to compounds or entities that alter, inhibit, activate, or otherwise affect biological or chemical events. For example, biologically active agents may be chemical entities or biological products that have therapeutic or diagnostic activity when delivered to a cell in vitro or delivered to the cell of the subject. The chemical entity or biological product can be an organic or inorganic molecule. In some embodiments, the biologically active agents are modified or unmodified polynucleotide. In some embodiments, the biologically active agents are peptides or peptidomimetics. In some embodiments, the one or more biologically active agents comprise proteins. In some embodiments, the one or more biologically active agents comprise nucleic acids (e.g. mRNA, gRNA or the combinations) . In some embodiments, one or more biologically active agents comprise vector comprising a nucleic acid encoding a therapeutic or diagnostic nucleic acids or proteins.
[0105] In some embodiments, the biologically active agent comprises a polypeptide, optionally in combination with a nucleic acid. In some embodiments, the biologically active agent comprises one or more nucleic acid, such as RNA (e.g. : siRNA, miRNA, shRNA, anti-sense RNA, mRNA, gRNA and the combinations or the like) . In some embodiments, the nucleic acid component comprises DNA. In some embodiments, the component, such as an RNA component may comprise an mRNA, such as an mRNA encoding an RNA-guided DNA-binding agent. In some embodiments, the RNA-guided DNA-binding agent is a Cas nuclease. In certain embodiments, the biologically active agent may comprise an mRNA that encodes Cas9, Cpf1, c2c2, cas12i, cas12f, cas12b, cas12c, cas12d, cas12e, cas12g, cas12j, cas12k or cas13. In certain embodiments, the biologically active agent may comprise a gRNA. In some biologically active agent comprising an mRNA encoding an RNA-guided DNA-binding agent, further comprises a gRNA nucleic acid, such as a gRNA. In some embodiments, the biologically active agent comprises an RNA-guided DNA-binding agent and a gRNA. In some embodiments, the biologically active agent comprises a Cas nuclease mRNA and a gRNA. In some embodiments, the biologically active agent comprises a Class 2 Cas nuclease mRNA and a gRNA. In some embodiments, the biologically active agent comprises a SpCas9 or / and an SaCas9, or a nucleic acid encoding such SpCas9 or / and an SaCas9; In some embodiments, the biologically active agent further comprises a gRNA.
[0106] “mRNA” refers to a polynucleotide and comprises an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by a ribosome and amino-acylated tRNAs) . mRNA can comprise a phosphate-sugar backbone including ribose residues or analogs thereof, e.g., 2'-methoxy ribose residues. In some embodiments, the sugars of an mRNA phosphate-sugar backbone consist essentially of ribose residues, 2'-methoxy ribose residues, or a combination thereof. In general, mRNAs do not contain a substantial quantity of thymidine residues (e.g., 0 residues or fewer than 30, 20, 10, 5, 4, 3, or 2 thymidine residues; or less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, or 0.1%thymidine content) . In some embodiments, an mRNA can contain modified uridines at some or all of its uridine positions. In some embodiments, the mRNA comprises pseudouridine modifications at some or all of its uridine positions; In some embodiments, the mRNA comprises N1-methyl-pseudouridine modifications at some or all of its uridine positions. In some embodiments, when synthesizing a modified mRNA, unmodified nucleotides are replaced with modified nucleotides, such as using pseudouridine or N1-methyl-pseudouridine instead of uridine.
[0107] “Cas nuclease” , as used herein, comprises DNA-binding agents (e.g. Cas cleavases, Cas nickases, and dCas) . Cas cleavases / nickases and dCas DNA-binding agents include a Csm or Cmr complex of a type III CRISPR system, the Cas10, Csm 1, or Cmr2 subunit thereof, a Cascade complex of a type I CRISPR system, the Cas3 subunit thereof, and Class 2 Cas nucleases. As used herein, a “Class 2 Cas nuclease” is a single-chain polypeptide with RNA-guided DNA-binding activity. Class 2 Cas nucleases include Class 2 Cas cleavases / nickases (e.g., H840A, D10A, or N863A variants) , which further have RNA-guided DNA cleavases or nickase activity, and Class 2 dCas DNA-binding agents, in which cleavase / nickase activity is inactivated. Class 2 Cas nucleases include, for example, Cas9, Cpf1, C2cl, C2c2, C2c3, HF Cas9 (e.g., N497A, R661A, Q695A, Q926A variants) , HypaCas9 (e.g., N692A, M694A, Q695A, H698A variants) , eSPCas9 (1.0) (e.g, K810A, K1003A, R1060A variants) , and eSPCas9 (1.1) (e.g., K848A, K1003A, R1060A variants) proteins and modifications thereof. In some embodiments, Cas9 is SpCas9 or SaCas9.
[0108] “Guide RNA” , “gRNA” , and simply “guide” are used herein interchangeably to refer to a cognate guide nucleic acid for an RNA-guided DNA-binding agent. Guide RNAs can include modified RNAs as described herein. A gRNA may be either a crRNA (also known as CRISPR RNA) , or the combination of a crRNA and a trRNA (also known as tracrRNA) . The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA) . “guide RNA” or “gRNA” refers to each type. The trRNA may be a naturally-occurring sequence, or a trRNA sequence with modifications or variations compared to naturally-occurring sequences.
[0109] In some embodiments, the sgRNA is a “Cas9 sgRNA” capable of mediating RNA guided DNA cleavage by a Cas9 protein. In some embodiments, the sgRNA is a “Cpf1 sgRNA” capable of mediating RNA-guided DNA cleavage by a Cpfl protein. In certain embodiments, the gRNA comprises a crRNA and a tracrRNA sufficient for forming an active complex with a Cas9 protein and mediating RNA-guided DNA cleavage. In certain embodiments, the gRNA comprises a crRNA sufficient for forming an active complex with a Cpf1 protein and mediating RNA-guided DNA cleavage.
[0110] In some embodiments, the delivery vehicles or the compositions, such as LNP, comprise modified nucleic acids, including modified RNAs. Modified nucleosides or nucleotides can be present in an RNA, for example a gRNA or mRNA. A gRNA or mRNA comprising one or more modified nucleosides or nucleotides, for example, is called a “modified” RNA to describe the presence of one or more non-naturally and / or naturally occurring components or configurations that are used instead of or in addition to the canonical A, G, C, and U residues. In some embodiments, a modified RNA is synthesized with a non-canonical nucleoside or nucleotide, here called “modified” or “modification. ”
[0111] Modified nucleosides and nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and / or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage (an exemplary backbone modification) ; (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar (an exemplary sugar modification) ; (iii) wholesale replacement of the phosphate moiety with “dephospho” linkers (an exemplary backbone modification) ; (iv) modification or replacement of a naturally occurring nucleobase, including with a non-canonical nucleobase (an exemplary base modification) ; (v) replacement or modification of the ribose-phosphate backbone (an exemplary backbone modification) ; (vi) modification of the 3′ end or 5′ end of the polynucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, cap or linker (such 3′ or 5′ cap modifications may comprise a sugar and / or backbone modification) ; and (vii) modification or replacement of the sugar (an exemplary sugar modification) . Certain embodiments comprise a 5′ end modification to an mRNA, gRNA, or nucleic acid. Certain embodiments comprise a modification to an mRNA, gRNA, or nucleic acid. Certain embodiments comprise a 3′ end modification to an mRNA, gRNA, or nucleic acid. A modified RNA can contain 5′ end and 3′ end modifications. A modified RNA can contain one or more modified residues at non-terminal locations. In certain embodiments, a gRNA includes at least one modified residue. In certain embodiments, an mRNA includes at least one modified residue.
[0112] In other embodiments, the modifications in this invention comprise modified phosphate groups include, phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral. The stereogenic phosphorous atom can possess either the “R” configuration (herein Rp) or the “S” configuration (herein Sp) . The backbone can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside) , with nitrogen (bridged phosphoroamidates) , sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates) . The replacement can occur at either linking oxygen or at both of the linking oxygens. The phosphate group can be replaced by non-phosphorus containing connectors in certain backbone modifications. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.
[0113] In some embodiments, modified sugars are believed to control the puckering ofnucleotide sugar rings, a physical property that influences oligonucleotide binding affinity for complementary strands, duplex formation, and interaction with nucleases. Substitutions on sugar rings can therefore alter the conformation and puckering of these sugars. For example, 2'-O-methyl (2'-OMe) modifications can increase binding affinity and nuclease stability of oligonucleotides.
[0114] The terms “mA” , “mC” , “mU” , or “mG” may be used to denote a nucleotide that has been modified with 2'-OMe.
[0115] A “*” may be used to depict a phosphorothioate (PS) modification. In this application, the terms A*, C*, U*, or G*may be used to denote a nucleotide that is linked to the next (e.g., 3') nucleotide with a PS bond.
[0116] In this application, the terms “mX” , “mN” , “mA” , “mC*” , “mU*” , or “mG*” may be used to denote a nucleotide that has been substituted with 2'-OMe or / and that is linked to the next (e.g., 3') nucleotide with a PS linkage, which may sometimes be referred to as a “PS bond” .
[0117] In this application, the terms “fX” , “fN” , “fA” , “fC*” , “fU*” , or “fG*” may be used to denote a nucleotide that has been substituted with 2'-F or / and that is linked to the next (e.g., 3') nucleotide with a PS linkage, which may sometimes be referred to as a “PS bond” .
[0118] In this application, the terms “pX” , “pA” , “pC*” , “pU*” , or “pG*” may be used to denote a nucleotide that has been substituted with 2'-phosphate or / and that is linked to the next (e.g., 3') nucleotide with a PS linkage, which may sometimes be referred to as a “PS bond” .
[0119] In this application, the terms “psX” , “psA” , “psC*” , “psU*” , or “psG*” may be used to denote a nucleotide that has been substituted with 2'-phosphorothioate or / and that is linked to the next (e.g., 3') nucleotide with a PS linkage, which may sometimes be referred to as a “PS bond” . Example types of modification gRNA in this invention can be descried as followings:
[0120] In some embodiments, a composition or formulation disclosed herein comprises an mRNA comprising an open reading frame (ORF) encoding an RNA-guided DNA-binding agent, such as a Cas nuclease, or Class 2 Cas nuclease as described herein. In some embodiments, an mRNA comprising an ORF encoding an RNA-guided DNA-binding agent, such as a Cas nuclease or Class 2 Cas nuclease, is provided, used, or administered. An mRNA may comprise one or more of a 5′ cap, a 5′ untranslated region (UTR) , a 3′ UTRs, and a polyadenine tail. The mRNA may comprise a modified open reading frame, for example to encode a nuclear localization sequence or to use alternate codons to encode the protein.
[0121] The mRNA in the disclosed LNP compositions may encode, for example, a secreted hormone, enzyme, receptor, polypeptide, peptide or other protein of interest that is normally secreted. In one embodiment of the invention, the mRNA may optionally have chemical or biological modifications which, for example, improve the stability and / or half life of such mRNA or which improve or otherwise facilitate protein production.
[0122] In addition, suitable modifications include alterations in one or more nucleotides of a codon such that the codon encodes the same amino acid but is more stable than the codon found in the wild-type version of the mRNA. For example, an inverse relationship between the stability of RNA and a higher number cytidines (Cs) and / or uridines (U′s) residues has been demonstrated, and RNA devoid of C and U residues have been found to be stable to most RNases (Heidenreich, et al. J Biol Chem 269, 2131-8 (1994) ) . In some embodiments, the number of C and / or U residues in an mRNA sequence is reduced. In another embodiment, the number of C and / or U residues is reduced by substitution of one codon encoding a particular amino acid for another codon encoding the same or a related amino acid. Contemplated modifications to the mRNA nucleic acids of the present invention also include the incorporation of pseudouridines. The incorporation of pseudouridines into the mRNA nucleic acids of the present invention may enhance stability and translational capacity, as well as diminishing immunogenicity in vivo. See, e.g., Kariko, K., et al., Molecular Therapy 16 (11) : 1833-1840 (2008) . Substitutions and modifications to the mRNA of the present invention may be performed by methods readily known to one or ordinary skill in the art.
[0123] The term modification also includes, for example, the incorporation of non-nucleotide linkages or modified nucleotides into the mRNA sequences of the present invention (e.g., modifications to one or both the 3′ and 5′ ends of an mRNA molecule encoding a functional secreted protein or enzyme) . Such modifications include the addition of bases to an mRNA sequence (e.g., the inclusion of a poly A tail or a longer poly A tail) , the alteration of the 3′ UTR or the 5′ UTR, complexing the mRNA with an agent (e.g., a protein or a complementary nucleic acid molecule) , and inclusion of elements which change the structure of an mRNA molecule (e.g., which form secondary structures) .
[0124] The poly A tail is thought to stabilize natural messengers. Therefore, in one embodiment a long poly A tail can be added to an mRNA molecule thus rendering the mRNA more stable. Poly A tails can be added using a variety of art-recognized techniques. For example, long poly A tails can be added to synthetic or in vitro transcribed mRNA using poly A polymerase (Yokoe, et al. Nature Biotechnology. 1996; 14: 1252-1256) . A transcription vector can also encode long poly A tails. In addition, poly A tails can be added by transcription directly from PCR products. In one embodiment, the length of the poly A tail is at least about 90, 200, 300, 400 at least 500 nucleotides. In one embodiment, the length of the poly A tail is adjusted to control the stability of a modified mRNA molecule of the invention and, thus, the transcription of protein. For example, since the length of the poly A tail can influence the half-life of an mRNA molecule, the length of the poly A tail can be adjusted to modify the level of resistance of the mRNA to nucleases and thereby control the time course of protein expression in a cell. In one embodiment, the stabilized mRNA molecules are sufficiently resistant to in vivo degradation (e.g., by nucleases) , such that they may be delivered to the target cell without a transfer vehicle.
[0125] In one embodiment, an mRNA can be modified by the incorporation 3′ and / or 5′ untranslated (UTR) sequences which are not naturally found in the wild-type mRNA. In one embodiment, 3′ and / or 5′ flanking sequence which naturally flanks an mRNA and encodes a second, unrelated protein can be incorporated into the nucleotide sequence of an mRNA molecule encoding a therapeutic or functional protein in order to modify it. For example, 3′ or 5′ sequences from mRNA molecules which are stable (e.g., globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzymes) can be incorporated into the 3′ and / or 5′ region of a sense mRNA nucleic acid molecule to increase the stability of the sense mRNA molecule. See, e.g., US2003 / 0083272. More detailed descriptions of the mRNA modifications can be found in US2017 / 0210698A1, at pages 57-68, the contents of which are incorporated herein.
[0126] The examples of the mRNA and gRNA used in this invention are shown in the following Tables.
[0127] Table 2: The exemplary mRNA used in this disclosure
[0128] The examples of the gRNA used in this invention are shown in the following Table 3:
[0129] Table 3: The exemplary gRNA used in this disclosure
[0130] Other Definitions:
[0131] It should be noted that, as used in this application, the singular form “a” , “an” and “the” and similar terms used in the context of the present disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, it should be noted that the plural form does not necessarily mean that it is plural, but may also include a singular form, and it needs to be understood according to the context in the article. Thus, for example, reference to “a composition” , “the composition” or “composition” includes a plurality of compositions and reference to “a cell” includes a plurality of cells and the like; Reference to “vehicles” comprises a plurality of vehicles and a vehicle.
[0132] The use of "or" or “and” is inclusive and means "and / or" unless stated otherwise.
[0133] When "t" or “T” appears in a sequence in this invention as a nucleotide of an RNA sequence, it should be understood as "u" or “U” .
[0134] As used herein, the term “delivering” , “delivery” or other derived terms, mean providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic vehicle to a subject may involve administering a nanoparticle composition including the therapeutic and / or prophylactic to the subject (e.g., by an intravenous, intramuscular, intradermal, or subcutaneous route) . Administration of a nanoparticle composition to a mammal or mammalian cell may involve contacting one or more cells with the nanoparticle composition.
[0135] As used herein, the term “contacting” means establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and a nanoparticle are made to share a physical connection. Methods of contacting cells with external entities both in vivo and ex vivo are well known in the biological arts. For example, contacting a nanoparticle composition and a mammalian cell disposed within a mammal may be performed by varied routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve varied amounts of nanoparticle compositions. Moreover, more than one mammalian cell may be contacted by a nanoparticle composition.
[0136] The terms "polynucleotide" , "nucleic acid" , or "oligonucleotide" refer to a polymer of nucleotides. The terms "polynucleotide" , "nucleic acid" , and "oligonucleotide" , may be used interchangeably. Typically, a polynucleotide comprises at least two nucleotides. DNAs and RNAs are polynucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) , nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5- methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O (6) -methylguanine, and 2-thiocytidine) , chemically modified bases, biologically modified bases (e.g., methylated bases) , intercalated bases, modified sugars (e.g., 2′-fluororibose, 2′-methoxyribose, 2′-aminoribose, ribose, 2′-deoxyribose, arabinose, and hexose) , unnatural base pairs (UBPs) , or modified phosphate groups (e.g., phosphorothioates and 5′-N phosphoramidite linkages) . Enantiomers of natural or modified nucleosides may also be used. Nucleic acids also include nucleic acid-based therapeutic agents, for example, nucleic acid ligands, siRNA, short hairpin RNA, antisense oligonucleotides, ribozymes, aptamers, and SPIEGELMERSTM, oligonucleotide ligands described in Wlotzka, et al., Proc. Natl. Acad. Sci. USA, 2002, 99 (13) : 8898, the entire contents of which are incorporated herein by reference. Nucleic acids can also include nucleotide analogs (e.g., BrdU) , and non-phosphodiester intemucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages) . In particular, nucleic acids can include, without limitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combination thereof.
[0137] The term "subject" refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal and particularly a human. Thus, the subject can be a human or veterinary patient. The term "patient" refers to a subject under the treatment of a clinician, e.g., physician.Examples
[0138] Example 1:
[0139] Methods:
[0140] 1. Oligonucleotide Barcode synthesis
[0141] The nucleic acid barcodes were prepared by modified oligonucleotides which designed rationally with several characteristics. Nucleic acid barcodes were 20-200 nucleotides in length, with or without the modifications described above. The barcode portion comprised 4-50 nucleotides in the center of the oligonucleotide.
[0142] 2. Nanoparticle Formulation
[0143] LNPs were formulated by mixing an aqueous phase containing nucleic acid with an ethanol phase containing lipids and excipients using a microfluidic chip device as previously described (Chen D, et al. (2012) Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc 134 (16) : 6948-6951) . Specifically, the ethanol phase contained a mixture of an ionizable lipid (e.g., 9, 12-Octadecadienoic acid (9Z, 12Z) -, 3- [4, 4-bis (octyloxy) -1-oxobutoxy] -2- [ [ [ [3- (diethylamino) propoxy] carbonyl] oxy] methyl] propyl ester, LP01, in this disclosure Lipid 40) , 1, 2-Dioctadecanoyl-sn-glycero-3-phophocholine (DSPC) , cholesterol, and 1, 2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000) . The ethanol phase was prepared by solubilizing a mixture. The aqueous phase was prepared in 25 mM citrate buffer with nucleic acid barcode and RNA (gRNA and mRNA, Table 2-3) . Each LNP was formulated to carry its own unique nucleic acid barcode. The resulting LNPs were dialyzed against TSS buffer contained 50 mM Tris, 45 mM NaCl, 5% (w / v) sucrose, pH 7.5 (TSS) in a 30,000 MWCO cassette at room temperature for 2 hours and then extruded through a 0.22 μm sterile filter. The final LNP was stored at -80 ℃ until further use. A series of ionizable lipids and formulations were used. The ionizable lipids used in the examples included the commercially available LP01, ALC-0315, MC3, 306-O12B, ALC-0366, as well as our proprietary ionizable lipids (Cationic lipids) , which have been documented in PCT / CN2024 / 074415, PCT / CN2023 / 108217, PCT / CN2023 / 108216, PCT / CN2023 / 120619 and PCT / CN2023 / 137046.
[0144] Nanoparticles with different compositions and with different barcodes were prepared by the similar method. All LNP contained 8 molar ratios of the four lipids, and each ratio is prepared by four different processes and 2 mass ratios between gRNA (e.g., sgRNA) and mRNA, any CRISPR-system could be used in performing the examples, for example, sgRNA targeting TTR and mRNA encoding SaCas9 or SpCas9 (which can be found in our previous work or description herein) are introduced in the examples. In should be understood that the mRNA used in the examples is N1-methyl-pseudouridine modified of the all the uracil.
[0145] 3. LNP characterization
[0146] LNP particle diameter and polydispersity were measured using dynamic light scattering (DLS) . Nanoparticles were diluted to ~0.001 mg / mL nucleic acid in PBS and analyzed at room temperature. We quantified RNA or DNA concentration and encapsulation as previously described and according to manufacturing instructions (Quant-iT RiboGreen RNA assay, Invitrogen R11490) .
[0147] Typically, when preparing LNPs, encapsulation was >80%, particle size was <150 nm, and PDI was < 0.2.
[0148] The values for average particle size, and polydispersity are reported in Table 4-9, for various LNP compositions.
[0149] The LNP compositions are listed in Table 10.
[0150] Table 4: Summary of LNP Formulation Data for rats
[0151] Table 5: Summary of LNP Formulation Data for NHP
[0152] Table 6: Summary of LNP Formulation Data for NHP
[0153] Table 7: Summary of LNP Formulation Data for mice
[0154] Table 8: Summary of LNP Formulation Data for mice
[0155] Table 9: Summary of LNP Formulation Data for NHP
[0156] Table 10: Summary of LNP compositions
[0157] 4. In vitro LNP delivery
[0158] The human hepatocellular carcinoma cell line HepG2 (American Type Culture Collection, Cat. HB-8065) was cultured at 37℃ and 5%CO2 in DMEM media supplemented with 10%fetal bovine serum. Cells were seeded in 48-well plates at a density of 20,000 cells per well. After 24 hours, cells were treated with Lipofectamine RNAiMAX encapsulating different barcodes at same concentration (6.25 nM) . After 72 hours transfection, cells were washed with PBS and genomic DNA was extracting using QuickExtract DNA Extraction Solution (Epicentre, QE09050) following the manufacturer′s recommended protocol.
[0159] 5. Animal experiments
[0160] All animals were purchased from Charles River Labs. For in vivo nanoparticle screens, 8-week-old male CD-1 mice were injected intravenously via the tail vein with a pool of different barcoded LNPs at a dose of 2 mg / kg. At 168 hours post-dose, all animals were euthanized for necropsy. Assessment of clinical signs, body weight, serum chemistry, organ weights and histopathology was performed. The cynomolgus monkeys were pretreated with dexamethasone at least 1 hour before Cyn-LNP infusion to mimic planned clinical pretreatment. The cynomolgus monkeys received intravenous administration of t LNP at doses of 3.0 mg / kg (total RNA / body weight) . Transthyretin (TTR) gene editing in liver was evaluated using next-generation sequencing on day 30 and 43. Serum target protein concentrations were assayed by ELISA. Liver or lung were cut into small slices, and genomic DNA was extracting using TIANamp Genomic DNA kit following the manufacturer′s recommended protocol.
[0161] 6. PCRAmplification
[0162] All samples were amplified and prepared for sequencing using a two-step, nested PCR. More specifically, 1 μL of primers (5 uM for Final Reverse / Forward) were added to 5 μL of Kapa HiFi 2X master mix (Roche) , and 4 μL template DNA / water. This first PCR reaction was run for 20 cycles. The second PCR, to add Nextera XT chemistry, indices, and i5 / i7 adapter regions was ran for 5-10 cycles and used the product from ‘PCR 1’ as template. Dual-indexed samples were run on a 2%agarose gel to ensure that PCR reaction occurred before being pooled and gel purified.
[0163] 7. Deep Sequencing
[0164] PCR samples were purified by AMPure XP beads. Final library QC was conducted using the Agilent Bioanalyzer 2100. Illumina deep sequencing was conducted on an Illumina MiniSeqTM. Primers were designed based on Nextera XT adapter sequences.
[0165] 8. Data Analysis &Barcode Delivery Quantification
[0166] Sequencing results were processed using a custom python-based tool to extract raw barcode counts for each tissue. These raw counts were then normalized with an R script prior to further analysis. The barcode counts were then normalized to 100%. Correlation analyses were run assuming a Gaussian distribution in order to obtain Pearson correlation coefficients. R2 values (0-1) were computed by squaring Pearson correlation coefficients.
[0167] 9. Barcode Delivery Normalization
[0168] LNP delivery of a specific barcode to cells or liver was calculated according to the following 3 steps: (i) dividing the number of sequencing reads of one barcode delivered by a single LNP formulation by the total amount of reads from all barcodes delivered by all LNPs in a specific tissue; (ii) dividing the number of sequencing reads of the same barcode (utilized in (i) ) by the total amount of reads from all barcodes of all LNPs in the non-injected LNP pool. (iii) dividing the results from (i) by the results from (ii) . By using this quantification method, the delivery of different LNP formulations within the same organ can be compared.
[0169] Results:
[0170] 1. Nucleic acid barcoded nanoparticles for high throughput in vivo nanoparticle delivery
[0171] We rationally designed nucleic acid barcodes in order to study the delivery of many LNPs at once. We formulated chemically distinct lipid nanoparticles (LNPs) so they each carried a unique nucleic acid barcode, sgRNA and Cas9 mRNA (Fig 1A) . LNP-1 carried RNA and nucleic acid barcode 1, whereas LNP-N carried RNA and nucleic acid barcode N. We pooled the different stable nanoparticle formulations together, and delivered the pool into cells, rats and non-human primates at the same times (Fig 1B) . At different time points, we isolated genomic DNA of tissues or cells. We used PCR with indexed primers to amplify the genomic fragment which was labeled by nucleic acid barcode and performed deep sequencing. By counting the nanoparticle-associated barcode sequences obtained from cells or tissues, we measured the relative biodistribution of many nanoparticles simultaneously.
[0172] 2. Barcoded screening system verification in vitro
[0173] We first tested the accuracy of this nucleic acid barcoded screening system using lipofectamine in vitro. Different doses of lipofectamine carried same dose RNA and nucleic acid barcodes were used to simulate different delivery efficiency of LNPs. The indel frequency which is positively correlated with delivery efficiency increased with the increasing lipofectamine dose (Fig 2) . The detected nucleic acid barcode counts were also positively correlated with the lipofectamine dose (Fig 3, 4) . The nucleic acid barcode dose can also affect indel frequency and barcode counts. Excessive nucleic acid barcode dose brings negative effect to indel frequency possible due to toxicity (Fig 5) . Within certain limits, nucleic acid barcode dose and counts are also positively correlated (Fig 6, 7) .
[0174] 3. LNP delivery into rat
[0175] We then pooled the 68 LNPs (Table 4) and intravenously injected them into rat at a total nucleic acid dose of 3 mg kg-1 (an average of 0.044 mg total nucleic acid / kg / particle) . Seven days after LNP administration, which is a sufficiently long time for functional cargo delivery to generate Cas9 / sgRNA ribonucleoprotein complexes (RNPs) , we isolated various tissues (heart, liver, spleen, lung, kidney, brain, ovary) and sequenced the barcodes using NGS. Next, we calculated the amount of delivery from each LNP by measuring the normalized delivery for each barcode. As we expected, LNPs are mainly delivered in the liver. According to the normalized nucleic acid barcode counts, total LNPs delivery was high in the liver, low in heart and spleen, and almost undetectable in other tissues (Fig 8) . To further analyze the efficiency of each LNP, we ranked LNPs by calculating the normalized delivery of each barcode or all 68 LNPs in liver (Fig 9) . To verify that the rank of the 68 LNPs in rats, 9 LNPs (representative from each high delivery, middle delivery and low delivery) were selected (Fig 10) . The individual LNP was intravenously injected into rat at a total nucleic acid dose of 3 mg kg-1. Seven days after LNP administration, delivery efficiency was detected.
[0176] 4. Efficiency comparison of barcode length in vitro
[0177] We then tested the efficiency of different length nucleic acid barcodes using same dose lipofectamine in vitro. The indel frequency is consistent which data is not shown. The barcode efficiency was different when using different length barcode (Fig 11) . Barcodes that are 31 bases (Barcodes 1-12 and barcodes 409-416) are more efficient than 33 bases (barcodes 103-116) . Therefore, the length of the barcode plays an important role in the efficiency of the entire system.
[0178] 5. Efficiency comparison of barcode length in vivo
[0179] We further tested the efficiency of different length nucleic acid barcodes using same LNP in vivo. LNP information was given in Table 5. We then pooled the 20 LNPs and intravenously injected them into non-human primate at a total nucleic acid dose of 3 mg kg-1 (an average of 0.15 mg total nucleic acid / kg / particle) . Twenty-eight days after LNP administration, which is a sufficiently long time for functional cargo delivery to generate Cas9 / sgRNA ribonucleoprotein complexes (RNPs) , we isolated liver and sequenced the barcodes using NGS. Consistent with the in vitro results, Barcodes that are 31 bases (LNP1-12) are more efficient than 33 bases (LNP 13-20) (Fig 12) .
[0180] 6. Lipid Screening with barcode system in non-human primates
[0181] Most important of all, the barcode system is a good choice to evaluate numerous lipids at the same time. 42 lipids were assessed in non-human primates. 79 LNPs information was given in Table 6. The efficiency of different lipid varies greatly (Fig 13) . Some lipids performed particularly well, such as lipid 3 (O- (heptadecan-9-yl) S- (6- ( (2-hydroxyethyl) (6- ( ( (nonyloxy) carbonyl) thio) hexyl) amino) hexyl) carbonothioate) , lipid 23 (O, O′-di (heptadecan-9-yl) S, S′- ( ( (4-hydroxybutyl) azanediyl) bis (hexane-6, 1-diyl) ) bis (carbonothioate) ) , lipid 32 (9- ( (6- ( ( (heptadecan-9-yloxy) carbonyl) thio) hexyl) (3-hydroxypropyl) amino) nonyl 2-butyloctanoate) and so on. This system is highly distinguishable from lipids. Technical repetition of the same lipid has high consistency at the same times.
[0182] 7. Validate the lipid optimized with barcode system in non-human primates
[0183] We further validated the preferred lipid (lipid 32) in vivo. LNP information was given in Table 7. We intravenously injected them into non-human primate at a total nucleic acid dose of 3 mg kg-1. Thirty and forty-three days after LNP administration, which is a sufficiently long time for functional cargo delivery to generate Cas9 / sgRNA ribonucleoprotein complexes (RNPs) , we isolated liver and sequenced the barcodes using NGS. The lipid 32 performed very well, the indel frequency is extremely high (Fig 14) . Reductions in serum TTR protein concentration from baseline were observed by day14 and deepened by day 28 (Figure 15) . At day 28 and beyond, TTR reductions more than 90%.
[0184] 8. Lipid Screening with barcode system in extrahepatic delivery in mice
[0185] We already confirm barcode system works in the liver, and it could work equally well in all organizations. 24 LNPs (Table 8) contained 19 lipids were formulated and assessed in the mice. We collected lung tissue after administrated the pooled LNPs and detected the barcodes in the samples. The differences between the lipids are even greater than liver. But we still can distinguish lipids of different efficiency (Fig 16) . We can evaluate lots lipids simultaneously, also in multiple organs. This data indicated that barcode system shows great potential for vehicle screening.
[0186] 9. Lipid Screening with barcode system in extrahepatic delivery in non-human primates
[0187] We further applied this barcode system in extrahepatic delivery in non-human primates. 229 LNPs information was given in Table 9. We pooled those LNPs and intravenously injected them into non-human primate at a total nucleic acid dose of 2 mg kg-1. Nineteen days after LNP administration, which is a sufficiently long time for functional cargo delivery to generate Cas9 / sgRNA ribonucleoprotein complexes (RNPs) , we isolated various tissues (heart, liver, spleen, lung, kidney, brain) and sequenced the barcodes using NGS. Next, we calculated the amount of delivery from each LNP by measuring the normalized delivery for each barcode. According to the normalized nucleic acid barcode counts, the performance of same LNP in different organs is different (Fig 17) . It is that enthusiasm that we can evaluate hundreds of LNPs in multiple organs simultaneously. This is a resource-saving and efficient method for LNP screening.
[0188] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1.A method for characterizing delivery vehicles for in vivo delivery of an agent comprising:(a) formulating multiple delivery vehicles having different compositions, wherein each different delivery vehicle comprises: i) one or more biologically active agents, and ii) one or more identifiers that identify the composition of the delivery vehicle;(b) administering the multiple delivery vehicles to cells or to a subject; and(c) identifying the identifiers by counting the vehicle-associated barcode sequences;wherein the biologically active agents can edit genome by performing biological activity when delivered to the cells in vitro or delivered to the cells of the subject.2.The method of claim 1, wherein the method further comprises isolating genomic DNA or RNA of tissues or cells and amplifying the genomic fragment before identifying the identifiers.3.The method of the claims 1 or 2, wherein the biologically active agents comprise RNA-guided DNA-binding agents or nucleic acid encoding the RNA-guided DNA-binding agents.4.The method of any one of the preceding claims 1-3, wherein the RNA-guided DNA-binding agents comprise Cas nuclease, preferably, the Cas nuclease is SpCas9 or SaCas9.5.The method of any one of the preceding claims 1-4, wherein the biologically active agents comprise gRNA, preferably, the gRNA is modified gRNA.6.The method of any one of the preceding claims 1-5, wherein the delivery vehicles comprise lipid nanoparticles (LNP) , virus derived vehicles, exosomes, extracellular contractile injection systems, bacterial derived delivery systems, cell derived delivery systems or combinations thereof.7.The method of any one of the preceding claims 1-7, wherein the delivery vehicles are LNP, preferably, each LNP comprises an ionizable lipid, a neutral lipid, a cholesterol and / or a PEG lipid.8.The method of any one of the preceding claims 1-7, wherein the structure of the ionizable lipids, the amount of ionizable lipids, the structure of PEG lipid, the amount of PEG lipid, the structure of neutral lipids, the amount of neutral lipids, and / or the amount of cholesterol are varied among the delivery vehicles.9.The method of any one of the preceding claims 1-8, wherein the process for preparing the vehicles varies among the delivery vehicles.10.The method of any one of the preceding claims 1-9, wherein the identifiers are capable of altering a target sequence when delivered to the cells in vitro or delivered to cells of a subject.11.The method of any one of the preceding claims 1-10, wherein the identifiers comprise nucleic acid barcodes.12.The method of any one of the preceding claims 1-11, wherein the nucleic acid barcodes comprise sequences to identify the composition of the delivery vehicles.13.The method of any one of the preceding claims 1-12, wherein the nucleic acid barcodes comprise DNA barcode oligonucleotides or RNA barcode oligonucleotides.14.The method of any one of the preceding claims 1-13, wherein the nucleic acid barcodes are single-stranded nucleic acids or double-stranded nucleic acids.15.The method of any one of the preceding claims 1-14, wherein the nucleic acid barcodes are 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.16.The method of any one of the preceding claims 1-15, wherein the nucleic acid barcodes comprise modified nucleotides, preferably, the modified nucleotides comprise phosphorylation at 5’ end and phosphorothioate linkage between the nucleotides of the sequences; preferably, the phosphorothioate linkage is between the last four nucleotides.17.The method of any one of the preceding claims 1-16, the molar ratio of the dosage of identifier to that of gRNA is 1: 5-1: 200, preferably, the molar ratio of the dosage of identifier to that of gRNA is 1: 40.18.The method of any one of the preceding claims 1-17, the tissues or cells are from liver, lung, spleen, heart, kidney, brain, bone marrow, lymph nodes, blood, T-cells, stem cells, ovary or testis.19.A composition comprising: one or more empty delivery vehicles, one or more nucleic acid barcodes, and one or more biologically active agents; wherein the biologically active agents can edit genome by performing biological activity when delivered to the cells in vitro or delivered to the cell of a subject.20.The composition of the preceding claim 19, wherein the biologically active agents comprise RNA-guided DNA-binding agents or nucleic acid encoding the RNA-guided DNA-binding agents.21.The composition of the preceding claim 19 or 20, wherein the RNA-guided DNA-binding agents comprise Cas nuclease, preferably, the Cas nuclease is SpCas9 or SaCas9.22.The composition of any one of the preceding claims 19-21, wherein the biologically active agents comprise gRNA, preferably, the gRNA is modified gRNA.23.The composition of any one of the preceding claims 1-22, wherein the delivery vehicles comprise lipid nanoparticles (LNP) , virus derived vehicles, exosomes, extracellular contractile injection systems, bacterial derived delivery systems, cell derived delivery systems or combinations thereof.24.The composition of any one of the preceding claims 19-23, wherein the delivery vehicles are LNP, preferably, each LNP comprises an ionizable lipid, a non-ionizable lipid, a cholesterol and / or a PEG lipid.25.The composition of any one of the preceding claims 19-24, wherein the structure of the ionizable lipids, the amount of ionizable lipids, the structure of PEG lipid, the amount of PEG lipid, the structure of neutral lipids, the amount of neutral lipids, and / or the amount of cholesterol are varied among the delivery vehicles.26.The composition of any one of the preceding claims 19-25, wherein the process for preparing the vehicles varies among the delivery vehicles.27.The composition of any one of the preceding claims 19-26, wherein nucleic acid barcodes are capable of altering a target sequence when delivered to the cells in vitro or delivered to cells of a subject.28.The composition of any one of the preceding claims 19-27, wherein the nucleic acid barcodes are DNA barcode oligonucleotides or RNA barcode oligonucleotides.29.The composition of any one of the preceding claims 19-28, wherein the nucleic acid barcodes are single-stranded nucleic acids or double-stranded nucleic acids.30.The composition of any one of the preceding claims 19-29, wherein the nucleic acid barcodes are 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.31.The composition of any one of the preceding claims 19-30, wherein the nucleic acid barcodes comprise modified nucleotides, preferably, the modified nucleotides comprise phosphorylation at 5’ end and phosphorothioate linkage between the nucleotides of the sequences; preferably, the phosphorothioate linkage is between the last four nucleotides.32.The composition of any one of the preceding claims 19-31, the molar ratio of the dosage of identifier to that of gRNA is 1: 5-1: 200, preferably, the molar ratio of the dosage of identifier to that of gRNA is 1: 40.33.A nucleic acid barcode composition according to the following formula: R1-R2-R3-R4-R5,wherein R1, R2, R3, R4 and R5 are independently selected from universal sequence, random nucleotide sequence, or barcode sequence.34.A nucleic acid barcode of the preceding claims 33, wherein the nucleic acid barcode comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100%sequence identity to any one of SEQ ID NOs: 1-341.
Citation Information
Patent Citations
Analysis of materials for tissue delivery
CN114144173A
Viral delivery vehicle selection
CN115768900A
Barcoded nanoparticles for specific targeting in vivo
US20200110083A1
Multiplexed Analysis of Materials for Tissue Delivery
US20200330607A1
Compositions and methods comprising ionizable lipid nanoparticies encapsulating barcoded mRNA
WO2021055892A1
